Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News WCC 2018

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

Todd Neale

December 06, 2018

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

Advertisement

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

TCTMD’s Top 10 Most Popular Stories for May 2024

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

CVD, Other Noncommunicable Diseases Hit Lower-Income Countries With Heavy Financial Burden

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content